Impact of antipsychotics on prolactin levels in youth with psychiatric disorders: A cross-sectional study

IF 5.3 2区医学 Q1 CLINICAL NEUROLOGY

Progress in Neuro-Psychopharmacology & Biological Psychiatry Pub Date : 2025-04-02 DOI:10.1016/j.pnpbp.2025.111349

Shuhei Wada , Kunihiro Iwamoto , Akira Yoshimi , Hirotake Hida , Shogo Hotta , Yukihiro Noda , Masashi Ikeda

{"title":"Impact of antipsychotics on prolactin levels in youth with psychiatric disorders: A cross-sectional study","authors":"Shuhei Wada , Kunihiro Iwamoto , Akira Yoshimi , Hirotake Hida , Shogo Hotta , Yukihiro Noda , Masashi Ikeda","doi":"10.1016/j.pnpbp.2025.111349","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The increasing prescription of antipsychotics for children and adolescents raises concerns regarding abnormal prolactin levels. However, prolactin monitoring is rarely conducted (0.1–10 %), and the prevalence and characteristics of abnormal prolactin levels remain unclear. This study aimed to investigate the prevalence of abnormal prolactin levels and identify the factors influencing serum prolactin levels in pediatric and adolescent patients treated with antipsychotics in a real-world clinical setting.</div></div><div><h3>Method</h3><div>This retrospective cross-sectional study was conducted at Nagoya University Hospital and included consecutive 489 patients with psychiatric disorders aged <18 years who underwent serum prolactin monitoring. Because all hospitalized patients were included, sampling bias was minimized. Data on patient demographics, psychiatric diagnoses, medications, and prolactin levels were extracted and analyzed. Multiple regression analysis was performed to identify the factors influencing serum prolactin levels. Analysis of covariance was used to assess the effects of different antipsychotics on prolactin levels.</div></div><div><h3>Results</h3><div>Hyperprolactinemia was observed in 23.0 % of patients treated with antipsychotics, whereas hypoprolactinemia was observed in 13.7 % of patients. Domperidone, sulpiride, and antipsychotics significantly increased prolactin levels. Risperidone, olanzapine, and blonanserin were associated with significantly increased serum prolactin levels, whereas aripiprazole was associated with hypoprolactinemia.</div></div><div><h3>Conclusion</h3><div>Approximately 40 % of pediatric patients treated with antipsychotics exhibited abnormal prolactin levels. Clinicians should routinely monitor prolactin levels and consider prolactin-related side effects when prescribing antipsychotics to children and adolescents. These findings emphasize the importance of tailored antipsychotic therapy to minimize the adverse effects in this vulnerable population.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"138 ","pages":"Article 111349"},"PeriodicalIF":5.3000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0278584625001034","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The increasing prescription of antipsychotics for children and adolescents raises concerns regarding abnormal prolactin levels. However, prolactin monitoring is rarely conducted (0.1–10 %), and the prevalence and characteristics of abnormal prolactin levels remain unclear. This study aimed to investigate the prevalence of abnormal prolactin levels and identify the factors influencing serum prolactin levels in pediatric and adolescent patients treated with antipsychotics in a real-world clinical setting.

Method

This retrospective cross-sectional study was conducted at Nagoya University Hospital and included consecutive 489 patients with psychiatric disorders aged <18 years who underwent serum prolactin monitoring. Because all hospitalized patients were included, sampling bias was minimized. Data on patient demographics, psychiatric diagnoses, medications, and prolactin levels were extracted and analyzed. Multiple regression analysis was performed to identify the factors influencing serum prolactin levels. Analysis of covariance was used to assess the effects of different antipsychotics on prolactin levels.

Results

Hyperprolactinemia was observed in 23.0 % of patients treated with antipsychotics, whereas hypoprolactinemia was observed in 13.7 % of patients. Domperidone, sulpiride, and antipsychotics significantly increased prolactin levels. Risperidone, olanzapine, and blonanserin were associated with significantly increased serum prolactin levels, whereas aripiprazole was associated with hypoprolactinemia.

Conclusion

Approximately 40 % of pediatric patients treated with antipsychotics exhibited abnormal prolactin levels. Clinicians should routinely monitor prolactin levels and consider prolactin-related side effects when prescribing antipsychotics to children and adolescents. These findings emphasize the importance of tailored antipsychotic therapy to minimize the adverse effects in this vulnerable population.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neuro-Psychopharmacology & Biological Psychiatry 医学-精神病学

CiteScore

12.00

自引率

1.80%

发文量

153

审稿时长

56 days

期刊介绍： Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject. Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.